Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

3 More Neil Woodford Core Picks For Your ISA: GlaxoSmithKline plc, Legal & General Group Plc & Imperial Brands PLC

Woodford core holdings GlaxoSmithKline plc (LON:GSK), Legal & General Group Plc (LON:LGEN) and Imperial Brands PLC (LON:IMB) could be great picks for your ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investors have plenty to worry about at the moment what with the upcoming UK referendum on EU membership, volatile commodity markets and a growth slowdown in China.

However, top fund manager Neil Woodford continues to believe that his equity income fund’s core blue-chip companies can still deliver in an uncertain and low-growth world.

If you’re looking for shares for your ISA in these difficult times, GlaxoSmithKline (LSE: GSK), Legal & General (LSE: LGEN) and Imperial Brands (LSE: IMB) — three Woodford core holdings — have a lot going for them.

GlaxoSmithKline

A Woodford fund update almost a year ago said: “GlaxoSmithKline is a long-term holding and one which has been frustratingly disappointing for much of the holding period”.

Last month, Glaxo reported a further decline in earnings in its annual results, the share price remains depressed … and Woodford and his team maintain their faith, saying recently: We continue to see substantial long-term value, believing that the sum of Glaxo’s constituent parts is significantly greater than the whole, as reflected by the current share price”.

Indeed, Woodford, and a number of other major shareholders, have for some time been calling for a radical, value-unlocking restructuring of Glaxo: a break-up, or partial break-up, of the four-business conglomerate.

An announcement last week that chief executive Sir Andrew Witty will retire in March next year could open the door for change. Not surprisingly, Woodford has expressed a “strong preference for an external candidate” to replace Witty.

Glaxo has decent prospects in its present form, with a return to growth expected this year, but there’s potential for shareholder returns to be significantly enhanced by the kind of restructuring Woodford and others are pressing for.

Legal & General

Insurer and asset manager Legal & General has seen its shares under pressure this year. The market has been concerned about the company’s corporate bond portfolio in an environment of deteriorating credit quality in the asset class, particularly in the troubled oil and mining sectors.

Woodford and his team are less concerned, saying early this month: We are reassured about its quality and diversity. We see [L&G’s] recent weakness as unjustified, given its strong cash generation, high yield and the fact that it looks well placed to deliver attractive rates of dividend growth.”

L&G has subsequently released results showing cash generation up 14% and a 19% dividend increase, giving ample support to Woodford’s view.

Imperial Brands

Imperial Brands has recently changed its name from Imperial Tobacco, but the business hasn’t changed and neither has Woodford’s positive view on the industry and the company.

Stephen Lamacraft, the Woodford team’s mature blue-chip specialist, recently reiterated that: “Tobacco has, over the years, proven itself to be an extremely dependable industry — delivering steady and sustainable growth in cash flows, earnings and dividends year in, year out, regardless of the economic environment”.

As far as Imperial Tobacco, in particular, is concerned, he added that last month’s trading update demonstrates “the stock’s attractive and dependable growth characteristics”.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The BP share price could face a brutal reckoning in 2026

Harvey Jones is worried about the outlook for the BP share price, as the global economy struggles and experts warn…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

How on earth did Lloyds shares explode 75% in 2025?

Harvey Jones has been pleasantly surprised by the blistering performance of Lloyds shares over the last year or two. Will…

Read more »

Group of four young adults toasting with Flying Horse cans in Brazil
Investing Articles

Down 56% with a 4.8% yield and P/E of 13 – are Diageo shares a generational bargain?

When Harvey Jones bought Diageo shares he never dreamed they'd perform this badly. Now he's wondering if they're just too…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Could these 3 holdings in my Stocks and Shares ISA really increase in value by 25% in 2026?

James Beard’s been looking at the 12-month share price forecasts for some of the positions in his Stocks and Shares…

Read more »

National Grid engineers at a substation
Investing Articles

2 reasons I‘m not touching National Grid shares with a bargepole!

Many private investors like the passive income prospects they see in National Grid shares. So why does our writer not…

Read more »

Number 5 foil balloon and gold confetti on black.
Investing Articles

£10,000 invested in Greggs shares 5 years ago would have generated this much in dividends…

Those who invested in Greggs shares five years ago have seen little share price growth. However, the dividends have been…

Read more »

Rolls-Royce Hydrogen Test Rig at Loughborough University
Growth Shares

Here is the Rolls-Royce share price performance for 2023, 2024, and 2025

Where will the Rolls-Royce share price be at the end of 2026? Looking at previous years might help us find…

Read more »

Investing Articles

This FTSE 250 stock could rocket 49%, say brokers

Ben McPoland takes a closer look at a market-leading FTSE 250 company that generates plenty of cash and has begun…

Read more »